Intra-CSF administered recombinant adenovirus causes an immune response-mediated toxicity

Gene Therapy

Volumn 7, Issue 16, 2000, Pages 1401-1409

  Driesse, M J ^a   Esandi, M C ^b   Kros, J M ^a   Avezaat, C J J ^a   Vecht, ChJ ^c   Zurcher, C ^c   Van Der Velde, I ^d   Valerio, D ^b,d   Bout, A ^b   Smitt, P AE Sillevis ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CRUCELL HOLLAND BV   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d LEIDEN UNIVERSITY   (Netherlands)

Author keywords

Cerebrospinal fluid; Gene therapy; Immune response; Recombinant adenovirus; Toxicity

Indexed keywords

GANCICLOVIR; INTERLEUKIN 6; INTERLEUKIN 8; VIRUS ANTIGEN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CONTROLLED STUDY; CYTOKINE RELEASE; DOSE RESPONSE; EYE DISEASE; FEMALE; GENE THERAPY; GENE TRANSFER; HISTOPATHOLOGY; HUMORAL IMMUNITY; HYPEREMIA; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; LETHARGY; MALE; MENINX DISORDER; METASTASIS; MONKEY; MONONUCLEAR CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TOXICITY; VIRUS CULTURE; VIRUS ISOLATION; VIRUS MENINGITIS; VIRUS RECOMBINANT; WEIGHT REDUCTION;

ADENOVIRIDAE; ANIMALIA; DNA VIRUSES; MACACA MULATTA; PRIMATES;

EID: 0033839344     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301250     Document Type: Article

References (43)

1. Leptomeningeal metastases
2. Tumor cells expressing the herpes simplex virus-thymidine kinase gene in the treatment of Walker 256 meningeal neoplasia in rats
3. Intrathecal gene therapy for malignant leptomeningeal neoplasia
4. Long-term survival in a rodent model of disseminated brain tumors by combined intrathecal delivery of herpes vectors and ganciclovir treatment
5. Treatment of leptomeningeal metastases in a rat model using a recombinant adenovirus containing the HSV-tk gene
6. Toxicity studies and distribution dynamics of retroviral vectors following intrathecal administration of retroviral vector-producer cells
7. Immune responses to reporter proteins and high viral dose limit duration of expression with adenoviral vectors: Comparison of E2a wild type and E2a deleted vectors
8. Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates
9. A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia
10. Interkeukin-1 mediates a rapid inflammatory response after injection of adenoviral vectors into the brain
11. Replication-deficient adenovirus induced expression of interleukin-8 by airway epithelial cells in vitro
12. Adenovirus infection stimulates the Raf/MAPK signaling pathways and induces interleukin-8 expression
13. Primates
14. A major role for viruses in acute childhood encephalopathy
15. Immediate inflammatory responses to adenovirus-mediated gene transfer in rat salivary glands
16. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration
17. Nonspecific inflammation inhibits adenovirus-mediated pulmonary gene transfer and expression independent of specific acquired immune responses
18. Adenovirus gene transfer causes inflammation in the brain
19. Adenoviral vector-mediated gene transfer in immuno competent Wister rats and T-cell deficient nude rats: Preferential survival of transduced glial cells in nude rats
20. Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis
21. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
22. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
23. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
24. Delayed-type hypersensitivity response to high dose of adenoviral vectors
25. Cytotoxic T lymphocyte responses to proteins encoded by heterologous transgenes transferred in vivo by adenoviral vectors
26. Immunological instability of persistent adenovirus vectors in the brain: Peripheral exposure to vector leads to renewed inflammation, reduced gene expression, and demyelination
27. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
28. Ovalbumin is more immunogenic when introduced into brain or cerebrospinal fluid than into extracerebral sites
29. Afferent and efferent arms of the humoral immune response to CSF-administered albumins in a rat model with normal blood-brain barrier permeability
30. Cervical lymphatics, the blood-brain barrier and immunoreactivity of the brain: A new view
31. Nervous tissue as an immune compartment: The dialect of the immune response in the CNS
32. The immunogenicity of intracerebral virus infection depends on anatomical site
33. Antigen-dependent intrathecal antibody synthesis in the normal rat brain: Tissue entry and local retention of antigen-specific B cells
34. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: Implications for clinical trials
35. Interleukin 6 enhances a cellular activity that functionally substitutes for E1A protein in transactivation
36. Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors
37. Growth, purification and titration of adenoviruses
38. Characterization of 911: A new helper cell-line for the titration and propagation of early region-1 deleted adenoviral vectors
39. In vivo adenovirus-mediated transfer of human CFTR cDNA to rhesus monkey airway epithelium: Efficacy, toxicity and safety
40. Detection, typing and subtyping of enteric adenoviruses 40 and 41 from fecal samples and observation of changing incidences of infections with these types and subtypes
41. A rhesus monkey model for continuous infusion of drugs into cerebrospinal fluid